Orlistat use in type 2 diabetes
OBJECTIVE: To review the use of orlistat in type 2 diabetes. DATA SOURCES: A MEDLINE search of the English-language literature (1990–August 2001) was performed using the key terms orlistat, obesity, glucose, and diabetes. DATA EXTRACTION: All articles pertaining to orlistat were considered for inclu...
Gespeichert in:
| Veröffentlicht in: | The Annals of pharmacotherapy 2002-07, Vol.36 (7), p.1210-1218 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1218 |
|---|---|
| container_issue | 7 |
| container_start_page | 1210 |
| container_title | The Annals of pharmacotherapy |
| container_volume | 36 |
| creator | Snider, LJ Malone, M |
| description | OBJECTIVE:
To review the use of orlistat in type 2 diabetes.
DATA SOURCES:
A MEDLINE search of the English-language literature (1990–August 2001) was performed using the key terms orlistat, obesity, glucose, and diabetes.
DATA EXTRACTION:
All articles pertaining to orlistat were considered for inclusion, with emphasis placed on randomized, placebo-controlled, double-blind clinical trials.
DATA SYNTHESIS:
In April 1999, orlistat was approved by the Food and Drug Administration for the treatment of obesity. Of 13 randomized, placebo-controlled studies, only 2 reported specific data in individuals with type 2 diabetes. Both reported significant weight reduction and improved glycemic control over placebo.
CONCLUSIONS:
Since weight loss is a difficult goal to achieve in patients with type 2 diabetes, orlistat can be a safe, effective addition to a multidisciplinary approach. |
| doi_str_mv | 10.1345/aph.1A422 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71856881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1A422</sage_id><sourcerecordid>71856881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-708378744d16411b80c194addc6c11e538db6f1e401d9438eb487e6a9c48d6e53</originalsourceid><addsrcrecordid>eNptkD1PwzAQhi0EoqUw8AcgC0gMKT7bsZ2xqviSKnWB2XIcp02Vj2InivrvMTRSF6Y76R7de_cgdAt4DpQlz3q_ncOCEXKGppAwEnMi8HnoMccxJhJP0JX3O4xxCiS9RBMgWPIk4VN0v3ZV6TvdRb23UdlE3WFvIxLlpc5sZ_01uih05e3NWGfo6_Xlc_ker9ZvH8vFKjZU0C4WWFIhBWM5cAaQSWwgZTrPDTcANqEyz3gBlmHIU0alzZgUluvUMJnzMJ-hx-PevWu_e-s7VZfe2KrSjW17rwTIhEsJAXw6gsa13jtbqL0ra-0OCrD6taGCDfVnI7B349I-q21-Isf3A_AwAtobXRVON6b0J46KIEyy03Veb6zatb1rgox_E0dwW262Q-ms8rWuqpAPahgGypUI6YDpDwZQfd8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71856881</pqid></control><display><type>article</type><title>Orlistat use in type 2 diabetes</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>Snider, LJ ; Malone, M</creator><creatorcontrib>Snider, LJ ; Malone, M</creatorcontrib><description>OBJECTIVE:
To review the use of orlistat in type 2 diabetes.
DATA SOURCES:
A MEDLINE search of the English-language literature (1990–August 2001) was performed using the key terms orlistat, obesity, glucose, and diabetes.
DATA EXTRACTION:
All articles pertaining to orlistat were considered for inclusion, with emphasis placed on randomized, placebo-controlled, double-blind clinical trials.
DATA SYNTHESIS:
In April 1999, orlistat was approved by the Food and Drug Administration for the treatment of obesity. Of 13 randomized, placebo-controlled studies, only 2 reported specific data in individuals with type 2 diabetes. Both reported significant weight reduction and improved glycemic control over placebo.
CONCLUSIONS:
Since weight loss is a difficult goal to achieve in patients with type 2 diabetes, orlistat can be a safe, effective addition to a multidisciplinary approach.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1A422</identifier><identifier>PMID: 12086556</identifier><identifier>CODEN: APHRER</identifier><language>eng</language><publisher>Los Angeles, CA: Harvey Whitney Books</publisher><subject>Anti-Obesity Agents - metabolism ; Anti-Obesity Agents - pharmacokinetics ; Anti-Obesity Agents - therapeutic use ; Biological and medical sciences ; Diabetes Mellitus - drug therapy ; Diabetes Mellitus, Type 2 - drug therapy ; General and cellular metabolism. Vitamins ; Glycated Hemoglobin A - drug effects ; Half-Life ; Humans ; Intestinal Absorption ; Lactones - metabolism ; Lactones - pharmacokinetics ; Lactones - therapeutic use ; Medical sciences ; Obesity ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic ; Treatment Outcome</subject><ispartof>The Annals of pharmacotherapy, 2002-07, Vol.36 (7), p.1210-1218</ispartof><rights>2002 SAGE Publications</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c373t-708378744d16411b80c194addc6c11e538db6f1e401d9438eb487e6a9c48d6e53</citedby><cites>FETCH-LOGICAL-c373t-708378744d16411b80c194addc6c11e538db6f1e401d9438eb487e6a9c48d6e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1345/aph.1A422$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1345/aph.1A422$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13791284$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12086556$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Snider, LJ</creatorcontrib><creatorcontrib>Malone, M</creatorcontrib><title>Orlistat use in type 2 diabetes</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>OBJECTIVE:
To review the use of orlistat in type 2 diabetes.
DATA SOURCES:
A MEDLINE search of the English-language literature (1990–August 2001) was performed using the key terms orlistat, obesity, glucose, and diabetes.
DATA EXTRACTION:
All articles pertaining to orlistat were considered for inclusion, with emphasis placed on randomized, placebo-controlled, double-blind clinical trials.
DATA SYNTHESIS:
In April 1999, orlistat was approved by the Food and Drug Administration for the treatment of obesity. Of 13 randomized, placebo-controlled studies, only 2 reported specific data in individuals with type 2 diabetes. Both reported significant weight reduction and improved glycemic control over placebo.
CONCLUSIONS:
Since weight loss is a difficult goal to achieve in patients with type 2 diabetes, orlistat can be a safe, effective addition to a multidisciplinary approach.</description><subject>Anti-Obesity Agents - metabolism</subject><subject>Anti-Obesity Agents - pharmacokinetics</subject><subject>Anti-Obesity Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Glycated Hemoglobin A - drug effects</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Intestinal Absorption</subject><subject>Lactones - metabolism</subject><subject>Lactones - pharmacokinetics</subject><subject>Lactones - therapeutic use</subject><subject>Medical sciences</subject><subject>Obesity</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Treatment Outcome</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkD1PwzAQhi0EoqUw8AcgC0gMKT7bsZ2xqviSKnWB2XIcp02Vj2InivrvMTRSF6Y76R7de_cgdAt4DpQlz3q_ncOCEXKGppAwEnMi8HnoMccxJhJP0JX3O4xxCiS9RBMgWPIk4VN0v3ZV6TvdRb23UdlE3WFvIxLlpc5sZ_01uih05e3NWGfo6_Xlc_ker9ZvH8vFKjZU0C4WWFIhBWM5cAaQSWwgZTrPDTcANqEyz3gBlmHIU0alzZgUluvUMJnzMJ-hx-PevWu_e-s7VZfe2KrSjW17rwTIhEsJAXw6gsa13jtbqL0ra-0OCrD6taGCDfVnI7B349I-q21-Isf3A_AwAtobXRVON6b0J46KIEyy03Veb6zatb1rgox_E0dwW262Q-ms8rWuqpAPahgGypUI6YDpDwZQfd8</recordid><startdate>20020701</startdate><enddate>20020701</enddate><creator>Snider, LJ</creator><creator>Malone, M</creator><general>Harvey Whitney Books</general><general>SAGE Publications</general><general>Whitney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020701</creationdate><title>Orlistat use in type 2 diabetes</title><author>Snider, LJ ; Malone, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-708378744d16411b80c194addc6c11e538db6f1e401d9438eb487e6a9c48d6e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Anti-Obesity Agents - metabolism</topic><topic>Anti-Obesity Agents - pharmacokinetics</topic><topic>Anti-Obesity Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Glycated Hemoglobin A - drug effects</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Intestinal Absorption</topic><topic>Lactones - metabolism</topic><topic>Lactones - pharmacokinetics</topic><topic>Lactones - therapeutic use</topic><topic>Medical sciences</topic><topic>Obesity</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Snider, LJ</creatorcontrib><creatorcontrib>Malone, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Snider, LJ</au><au>Malone, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Orlistat use in type 2 diabetes</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2002-07-01</date><risdate>2002</risdate><volume>36</volume><issue>7</issue><spage>1210</spage><epage>1218</epage><pages>1210-1218</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><coden>APHRER</coden><abstract>OBJECTIVE:
To review the use of orlistat in type 2 diabetes.
DATA SOURCES:
A MEDLINE search of the English-language literature (1990–August 2001) was performed using the key terms orlistat, obesity, glucose, and diabetes.
DATA EXTRACTION:
All articles pertaining to orlistat were considered for inclusion, with emphasis placed on randomized, placebo-controlled, double-blind clinical trials.
DATA SYNTHESIS:
In April 1999, orlistat was approved by the Food and Drug Administration for the treatment of obesity. Of 13 randomized, placebo-controlled studies, only 2 reported specific data in individuals with type 2 diabetes. Both reported significant weight reduction and improved glycemic control over placebo.
CONCLUSIONS:
Since weight loss is a difficult goal to achieve in patients with type 2 diabetes, orlistat can be a safe, effective addition to a multidisciplinary approach.</abstract><cop>Los Angeles, CA</cop><pub>Harvey Whitney Books</pub><pmid>12086556</pmid><doi>10.1345/aph.1A422</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1060-0280 |
| ispartof | The Annals of pharmacotherapy, 2002-07, Vol.36 (7), p.1210-1218 |
| issn | 1060-0280 1542-6270 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71856881 |
| source | SAGE Complete A-Z List; MEDLINE |
| subjects | Anti-Obesity Agents - metabolism Anti-Obesity Agents - pharmacokinetics Anti-Obesity Agents - therapeutic use Biological and medical sciences Diabetes Mellitus - drug therapy Diabetes Mellitus, Type 2 - drug therapy General and cellular metabolism. Vitamins Glycated Hemoglobin A - drug effects Half-Life Humans Intestinal Absorption Lactones - metabolism Lactones - pharmacokinetics Lactones - therapeutic use Medical sciences Obesity Pharmacology. Drug treatments Randomized Controlled Trials as Topic Treatment Outcome |
| title | Orlistat use in type 2 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A53%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Orlistat%20use%20in%20type%202%20diabetes&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Snider,%20LJ&rft.date=2002-07-01&rft.volume=36&rft.issue=7&rft.spage=1210&rft.epage=1218&rft.pages=1210-1218&rft.issn=1060-0280&rft.eissn=1542-6270&rft.coden=APHRER&rft_id=info:doi/10.1345/aph.1A422&rft_dat=%3Cproquest_cross%3E71856881%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71856881&rft_id=info:pmid/12086556&rft_sage_id=10.1345_aph.1A422&rfr_iscdi=true |